- Conditions
- Tobacco Use
- Interventions
- Patient navigation-based tobacco harm reduction intervention
- Other
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 190
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Asthma
- Interventions
- Benralizumab, Placebo
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Centennial, Colorado • Denver, Colorado + 16 more
- Conditions
- Social Determinants of Health, Breast Cancer, Prostate Cancer, Health Equity, Disparities
- Interventions
- Community Health Worker support
- Behavioral
- Lead sponsor
- Medstar Health Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine Sulfate
- Radiation · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 9 Years
- Enrollment
- 5,377 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2021
- U.S. locations
- 210
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 151 more
- Conditions
- Low Grade Glioma of Brain, Glioblastoma, Metastasis to Brain
- Interventions
- LUM Imaging System
- Combination Product
- Lead sponsor
- Lumicell, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Thyroid; Functional Disturbance, Hypothyroidism, Hemodialysis
- Interventions
- Levothyroxine Sodium, Placebos
- Drug
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Bladder Cancer, Glioma, Glioblastoma (GBM), Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer (GC), Pharynx Cancer, Oral Cavity Cancer, Kidney Cancer, Liver Cancer, Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Prostate Cancer
- Interventions
- [64Cu]CM500, [68Ga]CM500, PET/MR, PET/CT, Blood Collection
- Drug · Device · Procedure
- Lead sponsor
- Lumina Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Grand Rapids, Michigan • New York, New York
- Conditions
- Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Advanced Oropharyngeal Squamous Cell Carcinoma, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Interventions
- Fludeoxyglucose F-18, Positron Emission Tomography
- Radiation · Procedure
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Oropharynx Cancer
- Interventions
- De-escalated radiation dose, Standard radiation dose, 18 fluorodeoxyglucose (FDG)-positron emission tomography (PET)-Computed Tomography (CT)
- Radiation · Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 2
- States / cities
- Durham, North Carolina • Raleigh, North Carolina
- Conditions
- Multiple Myeloma
- Interventions
- Velcade, Thalidomide
- Drug
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 303 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2014
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Wound of Skin, Wound Heal, Wound Open, Surgical Wound
- Interventions
- 0.25% Timolol gel with paraffin gauze dressings, Vaseline dressing
- Drug · Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Obesity
- Interventions
- Tadalafil 20 MG, Placebo
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 19 Years to 50 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- PreDiabetes, Adult Children
- Interventions
- Metformin, Digital Intervention
- Drug · Behavioral
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 18 Years to 44 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- COVID, Corona Virus Infection, COVID19
- Interventions
- Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University., Placebo
- Biological · Other
- Lead sponsor
- Joanne Kurtzberg, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 5
- States / cities
- Boca Raton, Florida • Miami, Florida • Valhalla, New York + 1 more
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- 3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT, Computed Tomography, Positron Emission Tomography, Laboratory Biomarker Analysis
- Drug · Procedure · Other
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
- Interventions
- Chemotherapy, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cardiovascular Disease Other, Physical Activity
- Interventions
- Physical Activity Lifestyle Intervention, Physical Activity Monitoring
- Behavioral
- Lead sponsor
- Jamie Jackson
- Other
- Eligibility
- 18 Years to 25 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Pain, Chronic, Opioid Use Disorder
- Interventions
- Dissemination and Implementation Research
- Other
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,035 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Healthy
- Interventions
- PF-04995274
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- High Grade Glioma
- Interventions
- PET-MRI Brain Scan, Blood draw, Memory testing, Optional lumbar puncture for cerebrospinal fluid collection
- Procedure · Diagnostic Test · Behavioral
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Prednisone
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Substance Use Disorders, Opioid Use Disorder
- Interventions
- Patient Reported Outcome Measure
- Other
- Lead sponsor
- Brandeis University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Fall River, Massachusetts
- Conditions
- Glioblastoma Multiforme
- Interventions
- Amgen 386, Bevacizumab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Boston, Massachusetts • Worcester, Massachusetts + 2 more
- Conditions
- Opioid-related Disorders
- Interventions
- Interim Buprenorphine Treatment (IBT)
- Drug
- Lead sponsor
- University of Vermont Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Burlington, Vermont